To test a potential vaccine, scientists first administer it to a few people (at most, several dozen). Then researchers check to see if the vaccine caused volunteers’ immune systems to mount a defense against the disease they’re targeting. If it does, and if there aren’t severe side effects, the vaccine is tested on a larger group of 25 to 100 people.
During the final stage of testing, the vaccine is given to a group that can range between several hundred and thousands of people. At this stage, researchers give some volunteers the actual vaccine and others a placebo—a harmless substance that looks like the vaccine, but has no effect on the body. Some people from both groups will naturally be exposed to the targeted disease in their everyday environment. So, if fewer people who received the real vaccine get sick than those in the placebo group, scientists can be pretty sure the vaccine is doing its job. The large-scale trial helps researchers determine how effective the vaccine will be at protecting the overall population from getting sick. “Under normal circumstances, pharmaceutical companies’ approach to developing new vaccines is to start small and be cautious,” says Spencer. But for potential Covid-19 vaccines, scientists have raced through the early testing steps.
So far, more than 170 different coronavirus vaccines are in development worldwide. Only a few have made it to large-scale trials, the final step before approval. Russia and China have already authorized the emergency use of some vaccines their scientists developed. But the typical rigorous safety tests were not completed on those fast-tracked vaccines. The medicines have already been given to millions of people in those countries.
President Donald Trump has pushed to have a vaccine approved before the upcoming presidential election on November 3. Experts worry that political pressure to rush a coronavirus vaccine without the proper testing could be dangerous. Many people, too, have expressed wariness about the safety of a fast-tracked vaccine. A recent poll by the Pew Research Center found that only half of Americans would take a coronavirus vaccine if it were immediately available. Government scientists and pharmaceutical companies, though, have pledged to not release a coronavirus vaccine until they have enough data on its safety and ability to give people immunity. The right vaccine could save millions of lives in the U.S., which, as of October 20, has seen more than 225,000 deaths from Covid-19. Until a vaccine is ready, the U.S. Centers for Disease Control and Prevention says wearing a face mask, social distancing, and washing your hands often are the best tools against infection with the coronavirus.